탈모 매거진Hair Loss MagazineEuropean Medicines Agency Begins Review of Finasteride and Dutasteride for Potential Suicide Risk

European Medicines Agency Begins Review of Finasteride and Dutasteride for Potential Suicide Risk

Recent concerns have been raised in Europe regarding the potential link between finasteride and dutasteride, the primary ingredients in hair loss medications, and an increased risk of suicidal ideation. This has sparked significant social debate.
▲FROM : dailypharm(https://www.dailypharm.com/Users/News/NewsView.html?ID=316121&REFERER=NP)

Following an in-depth investigation by the European Medicines Agency (EMA), South Korea’s Ministry of Food and Drug Safety has also initiated a safety review of hair loss treatments, raising concerns among those affected by hair loss. Hair loss is a serious condition that impacts not only appearance but also an individual’s self-esteem and social life. As such, the safety concerns surrounding hair loss medications could result in broader societal issues beyond medical ones.

Medications like finasteride and dutasteride, which are DHT inhibitors, effectively prevent hair loss by blocking male hormones that contribute to the condition. However, some studies have suggested that long-term use of these drugs may lead to severe side effects, including sexual dysfunction, depression, and even suicidal ideation. One study highlighted that prolonged use might cause psychological changes in certain patients, indicating that the side effects extend beyond physical ones. While these side effects do not affect every user, they represent a significant concern for those taking the medication.

In Europe, in-depth reviews of the side effects of hair loss medications are already underway, and regulatory authorities in South Korea have also begun to address this issue This is an important step toward ensuring user safety. As hair loss medications are directly related to daily life, information about their side effects must be fully disclosed. Users have the right to make informed decisions, weighing the benefits of these drugs against the potential risks. Regulatory authorities must provide transparent information based on reliable data.

Concerns about hair loss medications and suicidal ideation should not be taken lightly. At the same time, attempts to exaggerate fears or downplay the issue should be avoided. Regulatory authorities must ensure a thorough review and offer transparent information to help those suffering from hair loss receive safe treatment.

In this context, BLMo-308, a plant-based natural product, may offer a safe and effective alternative. Unlike synthetic drugs, BLMo-308 is composed entirely of food-grade ingredients, making it less likely to cause side effects, even with long-term use. Additionally, clinical trial has shown its excellent efficacy in improving hair health, including increased hair density and thickness. As such, BLMo-308 could be a suitable alternative for individuals concerned about the risks associated with traditional synthetic drugs.

Drag